1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2021 2020 2019 2018 2017 2016 2015 2014
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
September 13, 2021
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
September 8, 2021
Resverlogix Announces Management Change
July 6, 2021
Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
June 22, 2021
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
June 3, 2021
Resverlogix Announces US$6 Million Debenture Financing
May 5, 2021
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
April 27, 2021
Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
April 20, 2021
Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
April 12, 2021
Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
March 17, 2021
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells
March 15, 2021
Resverlogix Announces Change in Fiscal Year-End to December 31
March 12, 2021
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
March 3, 2021
Resverlogix Reschedules Update Webcast and Conference Call
January 27, 2021
Resverlogix Announces Update Webcast and Conference Call
January 18, 2021
Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
January 12, 2021